Pseudomonas aeruginosa (P. aeruginosa) is a ubiquitous human pathogen causing different infections. Antibiotic therapy is the first clinical option for the infections caused by P. aeruginosa. Unfortunately, empiric antibiotic therapy may not work due to drug resistance. Non-antibitoc therapies for P. aeruginosa infections are getting extensive attention and promising research is being conducted. This review will focus on the progresses of non-antibitoc therapies including antigen-antibody immunotherapy, phage therapy and anti-virulence therapy. The problems of these new therapies in the clinical treatment and the possible strategies to overcome them are also discussed.